Inclisiran is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:
- in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin, or
- alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.1
Leqvio® is a first-in-class LDL-C-lowering therapy,1-3 with convenience of
• Subcutaneous injection
• No refrigeration required
• Fixed dose
* After an initial dose, Leqvio® is administered again at 3 months, followed by every 6 months.1
Leqvio® is not reimbursed in Ireland at this time.
Subcutaneous administration of Leqvio® :1
The recommended dose of inclisiran is 284 mg, administered via a single pre-filled syringe: as an initial dose, again at 3 months, followed by a dose every 6 months.
No dose adjustments are required for patients with mild or moderate hepatic impairment,† mild, moderate or severe renal impairment or end-stage renal disease,‡ or elderly patients.1
* After an initial dose, inclisiran is administered again at 3 months, followed by every 6 months.1
† No data are available in patients with severe hepatic impairment. Inclisiran should be used with caution in these patients.1
‡ There is limited experience with inclisiran in patients with severe renal impairment. Inclisiran should be used with caution in these patients. The effect of haemodialysis on inclisiran pharmacokinetics has not been studied. Haemodialysis should not be performed for at least 72 hours after inclisiran dosing.1
HCP, healthcare professional; LDL-C, low-density lipoprotein cholesterol.
Leqvio® Summary of Product Characteristics. Accessed August 2022 at www.ema.europe.eu
Stoekenbroek RM et al. Future Cardiol 2018;14(6):433–442.
Klinovski M et al. CADTH Issues in Emerging Health Technologies, 2019. Canadian Agency for Drugs and Technologies in Health.